中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.025 seconds)

    Methods for Treating HCV
    8.
    发明申请
    Methods for Treating HCV 审中-公开
    治疗HCV的方法

    公开(公告)号：US20150283199A1

    公开(公告)日：2015-10-08

    申请号：US14676378

    申请日：2015-04-01

    Applicant: AbbVie Inc.

    Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

    IPC: A61K38/06 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/7072

    CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

    Abstract translation: 本发明具有用于治疗HCV的无干扰素治疗。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 一方面，治疗包括给具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林，其中所述治疗持续12周，并且不包括施用干扰素，并且所述至少两种直接作用的抗病毒剂包含 a）化合物1或其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。

    Methods for Treating HCV
    9.
    发明申请
    Methods for Treating HCV 审中-公开

    公开(公告)号：US20150164976A1

    公开(公告)日：2015-06-18

    申请号：US14628849

    申请日：2015-02-23

    Applicant: AbbVie Inc.

    Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Scott C. Brun ,  Daniel E. Cohen ,  Emily O. Dumas ,  Sandeep Dutta ,  Amit Khatri ,  Cheri E. Klein ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki

    IPC: A61K38/07 ,  A61K31/427 ,  A61K31/7056 ,  A61K31/513 ,  A61K38/05

    CPC classification number: A61K38/07 ,  A61K31/402 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/12 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Patent Agency Ranking